Lytix Biopharma AS (OSL:LYTIX) ROCE % : -183.67% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lytix Biopharma AS's annualized ROCE % for the quarter that ended in Sep. 2024 was -183.67%.

Lytix Biopharma AS ROCE % Historical Data

The historical data trend for Lytix Biopharma AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lytix Biopharma AS ROCE % Chart

Lytix Biopharma AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-120.67

-251.50

-45.83

-34.40

-94.01

Lytix Biopharma AS Quarterly Data
	Dec18	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-96.06	-70.74	-175.52	-179.92	-183.67

Lytix Biopharma AS ROCE % Calculation

Lytix Biopharma AS's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-87.841	/	( ( (153.269 - 17.759)	+	(63.874 - 12.514) )	/ 2 )
	=	-87.841	/	( (135.51	+	51.36)	/ 2 )
	=	-87.841	/	93.435
	=	-94.01 %

Lytix Biopharma AS's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-92.192	/	( ( (77.665 - 16.178)	+	(56.283 - 17.379) )	/ 2 )
	=	-92.192	/	( ( 61.487	+	38.904 )	/ 2 )
	=	-92.192	/	50.1955
	=	-183.67 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Lytix Biopharma AS (OSL:LYTIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lytix Biopharma AS ROCE % Related Terms

Thank you for viewing the detailed overview of Lytix Biopharma AS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lytix Biopharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (OSL:LYTIX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

6BG:Germany

Address

Sandakerveien 138, Oslo, NOR, 0484

Website

https://www.lytixbiopharma.com

Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.

Lytix Biopharma AS Headlines

No Headlines